NEW CE PROGRAM

AdvancMed designates this educational activity for a maximum of
2.5 AMA PRA Category 1 Credit(s)™.
Physicians should only claim credit commensurate with the extent of their
participation in the activity.
About the CE Activity

Evolution in the Use of Boosted PIs as First-line Therapy: Factors to Consider will provide HIV-treating clinicians, including physicians, nurse practitioners, nurses, and pharmacists, with the most current clinical data on initial PI-based therapy. Recent studies have compared efficacy, safety, and metabolic parameters of PIs in head-to-head trials, and these are discussed, along with emerging data on drug-drug interactions and insulin resistance.

This print- and Internet-based CE activity contains PowerPoint slides, speaker notes, and references, and is a great resource for preparing educational lectures, as well as CME.

•

To receive a copy of the pocket resource compendium, you may request a copy online or
download a PDF at www.advancmed.org/1058

•To access the Internet activity and downloadable slides, please visit www.advancmed.org/1058W

For questions or assistance with either activity, call AdvancMed at 800-396-9577. The information is the same in each format, so you may only receive credit for one activity. Both activities are offered free of charge.

Continuing education (CE)
activity sponsored by
Made possible by an
educational grant from

CLICK HERE FOR COMPLETE PROGRAM DETAILS

Learning Objectives

After completing this educational activity, the participant should be able to:

•

determine appropriate choices for initial protease inhibitor therapy for HIV-infected patients;

•debate recent studies comparing the efficacy of protease inhibitors for treatment-naïve patients;
•compare the tolerability profiles of the protease inhibitor choices for treatment-naïve patients.

Co-Chairs

Graeme Moyle, MD, MB, BS, Dip GUM
Director of HIV Research Strategy
Chelsea and Westminster Hospital
London, United Kingdom 		Sharon Walmsley, MD
Associate Professor of Medicine
University of Toronto
Director of Clinical Research
Immunodeficiency Clinic, Toronto Hospital
Toronto, Ontario, Canada

CME Information

Accreditation Statements

AdvancMed is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AdvancMed is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

AdvancMed is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The ACPE Universal Program Number for the Resource Compendium activity is 397-000-07-004-H01. The ACPE Universal Program Number for the Internet activity is 397- 000-07-003-H01.

Credit Designation Statements

AdvancMed designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credit(s).™ Physicians should only claim credit commensurate with the extent of their participation in the activity.

AdvancMed provides this activity for 2.5 nursing contact hours.

AdvancMed provides this activity for 2.5 pharmacy contact hours (0.25 CEUs).

Acknowledgment of Commercial Support

AdvancMed gratefully acknowledges Roche Laboratories Inc. for the educational grant in support of this activity.